{"id":"somatostatin-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Somatostatin is a naturally occurring inhibitory peptide hormone that binds to somatostatin receptors (SSTR1-5) distributed across the gastrointestinal tract, pancreas, and immune system. When infused intravenously, it suppresses the release of various hormones (gastrin, secretin, motilin) and reduces mesenteric blood flow, thereby decreasing gastrointestinal secretions and motility. This mechanism is therapeutically exploited in acute variceal bleeding and other conditions involving excessive gastrointestinal hormone secretion.","oneSentence":"Somatostatin infusion activates somatostatin receptors on neuroendocrine and immune cells to inhibit hormone and cytokine secretion and reduce splanchnic blood flow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:29.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute variceal bleeding (esophageal or gastric varices)"},{"name":"Gastrointestinal hemorrhage control"}]},"trialDetails":[{"nctId":"NCT06991738","phase":"PHASE1, PHASE2","title":"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Thyroid Cancer","enrollment":18},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT03206060","phase":"PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-10","conditions":"Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors","enrollment":130},{"nctId":"NCT04711135","phase":"PHASE2","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2022-08-31","conditions":"Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma","enrollment":11},{"nctId":"NCT07246421","phase":"NA","title":"Glucagon Resistance in Patients With MASLD and T2DM","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2026-01-29","conditions":"Metabolic Associated Fatty Liver Disease, Type 2 Diabetes (T2DM)","enrollment":24},{"nctId":"NCT07366710","phase":"NA","title":"Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-05","conditions":"Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)","enrollment":36},{"nctId":"NCT07304466","phase":"NA","title":"Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Istanbul Medipol University Hospital","startDate":"2025-12-29","conditions":"Liver Transplantation, Portal Hypertension","enrollment":50},{"nctId":"NCT06416969","phase":"EARLY_PHASE1","title":"Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-01","conditions":"Obesity","enrollment":24},{"nctId":"NCT06441331","phase":"PHASE1","title":"Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","status":"RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2025-09-26","conditions":"Somatostatin Receptor Positive, NETs, Lymphoma","enrollment":20},{"nctId":"NCT04086485","phase":"PHASE1, PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-03","conditions":"Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms","enrollment":56},{"nctId":"NCT07252401","phase":"NA","title":"Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury","status":"NOT_YET_RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-12-25","conditions":"Liver Cirrhosis","enrollment":64},{"nctId":"NCT05636618","phase":"PHASE1, PHASE2","title":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Perspective Therapeutics","startDate":"2023-09-27","conditions":"Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor","enrollment":260},{"nctId":"NCT07178938","phase":"PHASE2","title":"Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-04-30","conditions":"Solid Tumors, HER2-positive Breast Cancer","enrollment":10},{"nctId":"NCT02799212","phase":"PHASE3","title":"Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-01-10","conditions":"Hepatocellular Carcinoma","enrollment":179},{"nctId":"NCT03000946","phase":"PHASE3","title":"Prevention of Postoperative Pancreatic Fistula by Somatostatin","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-15","conditions":"Pancreatic Surgery","enrollment":655},{"nctId":"NCT05387603","phase":"PHASE3","title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","status":"RECRUITING","sponsor":"Lund University Hospital","startDate":"2022-11-01","conditions":"Neuroendocrine Tumors","enrollment":300},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT03241706","phase":"PHASE1","title":"Liver Glycogen and Hypoglycemia in Humans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jason Winnick","startDate":"2018-08-02","conditions":"Hypoglycemia; Iatrogenic","enrollment":40},{"nctId":"NCT04837885","phase":"PHASE2","title":"Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-24","conditions":"Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour","enrollment":23},{"nctId":"NCT06732505","phase":"PHASE1","title":"A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-09-29","conditions":"Neuroendocrine Neoplasm","enrollment":36},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":"Neuroendocrine Tumors","enrollment":309},{"nctId":"NCT06974344","phase":"PHASE4","title":"Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)","status":"NOT_YET_RECRUITING","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2025-06-01","conditions":"Small-for-Size Syndrome","enrollment":80},{"nctId":"NCT04544098","phase":"EARLY_PHASE1","title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-02","conditions":"Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors","enrollment":10},{"nctId":"NCT02778425","phase":"NA","title":"The Treatment of Hepatocirrhosis and Portal Hypertension","status":"COMPLETED","sponsor":"Yanjing Gao","startDate":"2016-02","conditions":"Hepatic Cirrhosis, Portal Hypertension","enrollment":108},{"nctId":"NCT06411301","phase":"PHASE1","title":"A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2024-10","conditions":"Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma Progression","enrollment":""},{"nctId":"NCT02489604","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2013-12","conditions":"Neuroendocrine Tumors","enrollment":70},{"nctId":"NCT06143267","phase":"NA","title":"Neuronostatin - a Glucagonotropic Agent in Humans?","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2022-12-06","conditions":"Type 1 Diabetes, Hypoglycemia, Type1diabetes","enrollment":10},{"nctId":"NCT06607692","phase":"PHASE2","title":"Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).","status":"RECRUITING","sponsor":"Fundación de investigación HM","startDate":"2024-10","conditions":"Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma","enrollment":25},{"nctId":"NCT02236910","phase":"PHASE2","title":"An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2014-07","conditions":"Neuroendocrine Carcinoma","enrollment":66},{"nctId":"NCT05359146","phase":"EARLY_PHASE1","title":"Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-03-28","conditions":"Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)","enrollment":16},{"nctId":"NCT06240039","phase":"NA","title":"Direct Versus Indirect Effect of Amino Acids on Hepatokines","status":"NOT_YET_RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-02","conditions":"Non-Alcoholic Fatty Liver Disease, Obesity","enrollment":30},{"nctId":"NCT05871320","phase":"EARLY_PHASE1","title":"Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2022-12-23","conditions":"Neuroendocrine Tumors","enrollment":10},{"nctId":"NCT02592707","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs","status":"TERMINATED","sponsor":"Ipsen","startDate":"2017-03-06","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT04859322","phase":"NA","title":"The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover","status":"COMPLETED","sponsor":"Malte Palm Suppli, MD","startDate":"2021-02-08","conditions":"Non-Alcoholic Fatty Liver Disease, Glucagon Resistance","enrollment":20},{"nctId":"NCT02335580","phase":"","title":"Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2014-12","conditions":"Liver Cirrhosis, Portal Vein, Venous Thrombosis","enrollment":475},{"nctId":"NCT04915144","phase":"PHASE2","title":"177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs","status":"WITHDRAWN","sponsor":"British Columbia Cancer Agency","startDate":"2023-01-15","conditions":"Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor","enrollment":""},{"nctId":"NCT04949282","phase":"","title":"Spanish Series of Patients Treated With the Radionuclide Lutetium177","status":"RECRUITING","sponsor":"Sociedad Española de Medicina Nuclear e Imagen Molecular","startDate":"2021-05-10","conditions":"Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms","enrollment":5000},{"nctId":"NCT03998293","phase":"PHASE4","title":"Direct Measurement of Proinsulin Clearance in Humans","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2022-11","conditions":"Healthy","enrollment":""},{"nctId":"NCT04042142","phase":"NA","title":"Glucagon Resistance in Patients With NAFLD","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2019-10-05","conditions":"Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Glucose Metabolism Disorders","enrollment":28},{"nctId":"NCT03998709","phase":"PHASE4","title":"Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2020-02-01","conditions":"Healthy","enrollment":""},{"nctId":"NCT02748369","phase":"PHASE1","title":"In Vivo Assessment of Cellular Metabolism in Humans","status":"COMPLETED","sponsor":"K. Sreekumaran Nair","startDate":"2016-07","conditions":"Normal Cellular Metabolism","enrollment":17},{"nctId":"NCT05055713","phase":"NA","title":"A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-09-25","conditions":"Liver Cirrhosis, Esophageal and Gastric Varices, Hypersplenism","enrollment":368},{"nctId":"NCT04039516","phase":"PHASE2","title":"Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy","status":"UNKNOWN","sponsor":"King's College Hospital NHS Trust","startDate":"2020-10","conditions":"Carcinoid Heart Disease, Carcinoid Syndrome, Carcinoid Tumor","enrollment":20},{"nctId":"NCT04029428","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression","status":"UNKNOWN","sponsor":"University of Warmia and Mazury","startDate":"2004-11-02","conditions":"Neuroendocrine Tumors","enrollment":150},{"nctId":"NCT03349424","phase":"PHASE4","title":"Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2018-06-22","conditions":"Pancreatic Fistula","enrollment":205},{"nctId":"NCT01865760","phase":"NA","title":"Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2013-06","conditions":"Obesity, Hypoglycemia, Surgery","enrollment":33},{"nctId":"NCT04107428","phase":"PHASE4","title":"Somatostatin in Living Donor Liver Transplantation","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2019-12","conditions":"End Stage Liver DIsease, Portal Hypertension","enrollment":56},{"nctId":"NCT02971202","phase":"PHASE1","title":"Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-12","conditions":"Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2","enrollment":33},{"nctId":"NCT04010669","phase":"PHASE3","title":"The Role of Somatostatin in the Hemodynamics of the Hepatic Circulation in Patients Undergoing Liver Resection","status":"UNKNOWN","sponsor":"Laikο General Hospital, Athens","startDate":"2019-08-01","conditions":"Portal Hypertension","enrollment":40},{"nctId":"NCT03846180","phase":"","title":"Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2019-03-01","conditions":"Variceal Hemorrhage, Cirrhosis, Liver, Kidney Injury","enrollment":1682},{"nctId":"NCT02337660","phase":"NA","title":"Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2015-01","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":30},{"nctId":"NCT02705313","phase":"","title":"EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx","status":"APPROVED_FOR_MARKETING","sponsor":"Advanced Accelerator Applications","startDate":"","conditions":"Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT02217800","phase":"PHASE2","title":"The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"2013-11","conditions":"Acromegaly","enrollment":8},{"nctId":"NCT03013387","phase":"PHASE2","title":"Dosimetry Guided PRRT With 90Y-DOTATOC","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2017-01","conditions":"Neuroendrocrine Tumors, Meningioma, Neuroblastoma","enrollment":""},{"nctId":"NCT02023489","phase":"NA","title":"Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Familiar Hypocalcuric Hypercalcemia","enrollment":90},{"nctId":"NCT00049023","phase":"PHASE1","title":"Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors","status":"COMPLETED","sponsor":"O'Dorisio, M S","startDate":"2002-01","conditions":"Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor","enrollment":27},{"nctId":"NCT02757703","phase":"PHASE4","title":"Vasoactive Drugs in Real World Practice","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2010-05","conditions":"Vasoconstrictor Choice on Acute Variceal Bleeding","enrollment":150},{"nctId":"NCT01860742","phase":"PHASE3","title":"Randomized Phase III of PRRT Versus Interferon","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2014-12","conditions":"Gastro-intestinal Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT02012166","phase":"PHASE1","title":"A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT02311608","phase":"","title":"Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2014-02","conditions":"Liver Cirrhosis, Esophageal and Gastric Varices, Hemorrhage","enrollment":1320},{"nctId":"NCT01290172","phase":"PHASE1","title":"Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2010-12","conditions":"Liver Transplant With Clinically Significant Portal Hypertension","enrollment":33},{"nctId":"NCT01897844","phase":"PHASE1","title":"A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2013-05","conditions":"Healthy","enrollment":36},{"nctId":"NCT01053390","phase":"PHASE3","title":"New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-10","conditions":"Gallbladder Neoplasms","enrollment":216},{"nctId":"NCT01665638","phase":"PHASE1","title":"Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-09","conditions":"Healthy","enrollment":10},{"nctId":"NCT00006368","phase":"PHASE1","title":"Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"1998-01","conditions":"Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor","enrollment":60},{"nctId":"NCT01062529","phase":"NA","title":"Peripheral Metabolic Effects of Somatostatin","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2009-10","conditions":"Acromegaly, Growth Hormone Deficiency, Diabetes","enrollment":8},{"nctId":"NCT00152399","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2000-09","conditions":"Peptic Ulcer","enrollment":370},{"nctId":"NCT01431781","phase":"NA","title":"The Prophylactic Effect of Stilamin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2011-08","conditions":"Post-ERCP Acute Pancreatitis","enrollment":908},{"nctId":"NCT01082627","phase":"PHASE4","title":"Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction","status":"COMPLETED","sponsor":"Nanjing PLA General Hospital","startDate":"2009-06","conditions":"Small Bowel Obstruction","enrollment":44},{"nctId":"NCT01060826","phase":"PHASE3","title":"Efficacy of Administration of Somatostatin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2009-05","conditions":"Acute Pancreatitis","enrollment":510},{"nctId":"NCT01267669","phase":"NA","title":"A Trial of Somatostatin With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding","status":"COMPLETED","sponsor":"Govind Ballabh Pant Hospital","startDate":"2005-11","conditions":"Acute Bleeding Esophageal Varices, Portal Hypertension, Cirrhosis","enrollment":61},{"nctId":"NCT01112852","phase":"PHASE4","title":"EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding","status":"COMPLETED","sponsor":"National Science and Technology Council, Taiwan","startDate":"2006-12","conditions":"Esophageal Varices, Bleeding","enrollment":118},{"nctId":"NCT01060917","phase":"PHASE1, PHASE2","title":"Glucose Clamp Study to Prove Hypo- and Hyperglycemic Episodes Using a Non-invasive Glucose Monitoring Device","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2003-01","conditions":"Diabetes Mellitus","enrollment":21},{"nctId":"NCT01058577","phase":"PHASE1","title":"Changes in Serum Electrolytes at Different Glucose Concentrations + Impact on a Non-invasive Glucose Monitoring Method","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2001-12","conditions":"Diabetes Mellitus","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"somatostatin infusion","genericName":"somatostatin infusion","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Somatostatin infusion activates somatostatin receptors on neuroendocrine and immune cells to inhibit hormone and cytokine secretion and reduce splanchnic blood flow. Used for Acute variceal bleeding (esophageal or gastric varices), Gastrointestinal hemorrhage control.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}